Phase II study of bleomycin, dacarbazine (DTIC) and vindesine in disseminated malignant melanoma

J Cancer Res Clin Oncol. 1989;115(1):93-5. doi: 10.1007/BF00391607.

Abstract

Thirty-one patients with disseminated malignant melanoma were treated with a combination chemotherapy of bleomycin, dacarbazine and vindesine. Five complete responses, and five partial remissions occurred. One patient survived for over 2 years without evidence of disease. This combination of drugs may give better results, as far as complete recovery and long-term survival are concerned, than single-agent therapy with dacarbazine.

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Bleomycin / administration & dosage
  • Dacarbazine / administration & dosage
  • Female
  • Humans
  • Male
  • Melanoma / drug therapy*
  • Middle Aged
  • Vindesine / administration & dosage

Substances

  • Bleomycin
  • Dacarbazine
  • Vindesine